Radecki v. GlaxoSmithKline

646 F. Supp. 2d 310, 2009 U.S. Dist. LEXIS 74303, 92 Empl. Prac. Dec. (CCH) 43,672, 2009 WL 2595955
CourtDistrict Court, D. Connecticut
DecidedAugust 21, 2009
DocketCivil 3:06cv00849(AWT)
StatusPublished
Cited by5 cases

This text of 646 F. Supp. 2d 310 (Radecki v. GlaxoSmithKline) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Radecki v. GlaxoSmithKline, 646 F. Supp. 2d 310, 2009 U.S. Dist. LEXIS 74303, 92 Empl. Prac. Dec. (CCH) 43,672, 2009 WL 2595955 (D. Conn. 2009).

Opinion

RULING ON MOTION TO DISMISS WITH PREJUDICE AND FOR COSTS AND FEES

ALVIN W. THOMPSON, District Judge.

The defendant has moved for a sanction in the form of dismissal with prejudice of the plaintiffs claims in this action or, in *312 the alternative, for an award of costs and fees associated with the mistrial declared in this action and the instant motion. For the reasons set forth below, the court is dismissing the plaintiffs case with prejudice.

I. STATEMENT OF FACTS

Plaintiff D. Brian Radecki (“Radecki”) commenced employment with defendant GlaxoSmithKline (“GSK”) on February 5, 2001 as a pharmaceutical sales representative. Radecki injured his knee in May 2004 and went on leave from May 25 to July 29, 2004 under the Family and Medical Leave Act of 1993 (“FMLA”), 29 U.S.C. § 2601 et seq. He subsequently took a second medical leave from August 13 to August 31, 2004 and a third medical leave from February 18 to May 27, 2005, both relating to the same knee injury. On June 7, 2005, GSK terminated his employment.

Radecki filed this action, claiming that GSK terminated his employment in retaliation for him exercising his rights under the FMLA, terminated his employment in retaliation for him engaging in protected speech, in violation of Connecticut General Statutes § 31-51q, and terminated his employment in violation of public policy. GSK contends that it terminated Radecki’s employment only after a compliance investigation revealed that the plaintiff had, on at least ten different occasions, falsified company records regarding his call reporting activities, and then only after allowing him to take advantage of FMLA leave it had approved. The court granted summary judgment in favor of GSK on the second claim, and the case proceeded to trial on the FMLA retaliation and wrongful termination in violation of public policy claims.

Because Radecki had only worked for a relatively short period during the almost four years since GSK terminated his employment, one of the issues at trial was whether he had mitigated damages. During his direct examination on May 7, 2009, Radecki’s attorney asked him about his efforts to find work after the date on which GSK terminated his employment. The pertinent testimony is as follows:

Q: Did there ever come a time that you stopped looking for work?
A: Yes.
Q: When?
A: In November of last year.
Q: Why?
A: Because of the last week of October I learned that I had- — have stage III prostate cancer with a metastatic brain lesion.
Q. How long did that — did you get treatment for that?
A. Yes.
Q. When was that concluded?
A. Well, the major — the major conclusion was I had surgery in January.
Q. Did you resume your job search after that?
A. I have at least on paper. I’m still in rehabilitative mode.

(Trial Tr. Vol. I, 152, May 7, 2009.) The plaintiffs counsel had not known anything about “a metastatic brain lesion” until his testimony was given.

After the jury had been excused for the day, defense counsel expressed a concern that “Radecki’s Stage III metastatic cancer was not disclosed” to the defense, notwithstanding the pertinent interrogatory and production request that had been propounded by the defendant, and stated that had it been disclosed, the defense, would have moved in limine with respect to that evidence. Id. at 193. The plaintiffs counsel stated in response that a document provided a week earlier, i.e., a copy of Radecki’s request for an extension for paying his taxes for 2008, which admittedly was not responsive to the pertinent inter *313 rogatory and production request, contained a statement that Radecki had undergone cancer treatment. The court did not address that issue but, rather, observed that had a motion in limine been filed, it would have been granted and that the plaintiff would have been allowed only to make a general reference to health problems. The court and counsel agreed to consider the matter overnight and discuss it further the next morning.

The next morning, the defense informed the court that it was moving for a mistrial. In support of its motion for a mistrial, the defense argued first that “[t]he assumption ... that juries will follow limiting and curative instructions does not apply when prejudice is so severe that the instructions would be ineffective.” (Trial Tr. Vol. II, 199, May 8, 2009) (citing United States v. Hamdy, No. 05-CR-232S, 2006 U.S. Dist. LEXIS 44043, at *6 (W.D.N.Y. June 28, 2006) (citation and internal quotation marks omitted)). The defense contended that the prejudice was so severe here so as to render a curative instruction ineffective because, based on Radecki’s statement that he had stage III prostate cancer with a metastatic brain lesion, the jury could reasonably infer that Radecki was dying. The court agreed that such an inference would be a reasonable one. In addition, the defense pointed to a concern that when Radecki was asked if he was looking for a job after his surgery, he said “on paper,” and whereas the defense would ordinarily confront a witness who gave such a response about his effort to mitigate damages, if the defense sought to confront the plaintiff on that point, it would simply remind the jury about his cancer. At the point the motion for a mistrial was made, the defense proceeded with the understanding that Radecki had a metastatic brain lesion, as did Radecki’s counsel and the court. The court and counsel discussed various options as to how to proceed. The court eventually decided to require the plaintiff to obtain and deliver to the defense all his medical records, and also decided to meet with counsel later that day after defense counsel had an opportunity to review the medical records. After the parties were informed that the plaintiff would be required to turn over his medical records, Radecki had a private conversation with his counsel, immediately after which his counsel stated:

I just want to clarify one other issue, I don’t know if we need to go any further with it. With respect to the illness and the treatment itself, he had the surgery and the postoperative course. Right now apparently he’s clear. The brain issue is not an issue — what showed up on the imaging had not progressed, didn’t warrant treatment. I wanted you to understand. You mentioned the issue that they could be concerned that he might be [dying], we could actually resolve that if you want to. He’s apparently clear now.

(Trial Tr. Vol. II, 213, May 8, 2009.) The jury was excused for the day, and a recess followed.

On the afternoon of May 8, the court continued the hearing after the defense had had an opportunity to review the plaintiffs medical records. Radecki’s medical records reflect that he was given a whole body bone scan on October 2, 2008.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Radecki v. GlaxoSmithKline
375 F. App'x 46 (Second Circuit, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
646 F. Supp. 2d 310, 2009 U.S. Dist. LEXIS 74303, 92 Empl. Prac. Dec. (CCH) 43,672, 2009 WL 2595955, Counsel Stack Legal Research, https://law.counselstack.com/opinion/radecki-v-glaxosmithkline-ctd-2009.